Cargando…

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose

OBJECTIVES: This study aimed to describe the longitudinal evolution of neutralizing antibody titres (NtAb) in three different cohorts of healthcare workers (HCWs), including vaccinated HCWs with and without a previous SARS-CoV-2 infection and previously infected unvaccinated HCWs. COVID-19 was mild...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vicenti, Ilaria, Basso, Monica, Gatti, Francesca, Scaggiante, Renzo, Boccuto, Adele, Zago, Daniela, Modolo, Eliana, Dragoni, Filippo, Parisi, Saverio Giuseppe, Zazzi, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410637/ https://www.ncbi.nlm.nih.gov/pubmed/34481967 http://dx.doi.org/10.1016/j.ijid.2021.08.052

Ejemplares similares

The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection
por: Vicenti, Ilaria, et al.
Publicado: (2022)

Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses
por: Parisi, Saverio Giuseppe, et al.
Publicado: (2022)

Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals
por: Boccuto, Adele, et al.
Publicado: (2021)

SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility
por: Luongo, Francesca P., et al.
Publicado: (2022)

SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy
por: Vicenti, Ilaria, et al.
Publicado: (2023)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
por: Basso, Monica, et al.
Publicado: (2021)

388. Multidrug Resistant Gram Negative Organisms Prevalence in Hospitalized Patients in an Italian Tertiary Level Hospital During COVID-19 Pandemia: First Detection is More Frequent in Clinical Samples than in Surveillance Rectal Swabs with Respect to the Previous 14-Month Period
por: Basso, Monica, et al.
Publicado: (2020)

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications
por: Parisi, Saverio Giuseppe, et al.
Publicado: (2019)

Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro
por: Boccuto, Adele, et al.
Publicado: (2021)

Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection
por: Parisi, Saverio Giuseppe, et al.
Publicado: (2017)

HCV RNA viral load is independent from CD4 cell count and plasma HIV RNA viral load in immunocompetent HIV-HCV co-infected patients: a 3-years follow-up study
por: Basso, Monica, et al.
Publicado: (2014)

In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study
por: Cirri, Damiano, et al.
Publicado: (2021)

2506. Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004–2019
por: Basso, Monica, et al.
Publicado: (2019)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Cytomegalovirus, Epstein-Barr virus and human herpesvirus 8 salivary shedding in HIV positive men who have sex with men with controlled and uncontrolled plasma HIV viremia: a 24-month longitudinal study
por: Basso, Monica, et al.
Publicado: (2018)

Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection
por: Baos, Elvira, et al.
Publicado: (2022)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
por: Prendecki, Maria, et al.
Publicado: (2021)

Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection
por: Bongiovanni, Marco, et al.
Publicado: (2021)

Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination
por: Raw, Rachael Kathleen, et al.
Publicado: (2021)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
por: Perkmann, Thomas, et al.
Publicado: (2023)

SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine
por: Anderson, Mark, et al.
Publicado: (2021)

Anal and oral human papillomavirus (HPV) infection in HIV-infected subjects in northern Italy: a longitudinal cohort study among men who have sex with men
por: Parisi, Saverio G, et al.
Publicado: (2011)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
por: Efrati, Shai, et al.
Publicado: (2021)

Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
por: Muena, Nicolás A., et al.
Publicado: (2022)

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2
por: Siracusano, Gabriel, et al.
Publicado: (2022)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
por: Lombardi, Andrea, et al.
Publicado: (2021)

Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm
por: Luddi, Alice, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f17sffs7rbhi8t59dk8hrkaphu